机译:靶向癌症治疗色氨酸代谢的靶向调节:系统审查
Guangxi Bot Garden Med Plant Natl Engn Lab Dev Southwestern Endangered Med Mat Nanning Guangxi Peoples R China;
Heilongjiang Univ Chinese Med Sinoamer Chinmed Technol Collaborat Ctr Natl TCM Key Lab Serum Pharmacochem Lab Metab Chinmed Res Ctr State Adm TCM Dept Pharmaceut Ana Heping Rd 24 Harbin Heilongjiang Peoples R China;
Guangxi Bot Garden Med Plant Natl Engn Lab Dev Southwestern Endangered Med Mat Nanning Guangxi Peoples R China;
Heilongjiang Univ Chinese Med Sinoamer Chinmed Technol Collaborat Ctr Natl TCM Key Lab Serum Pharmacochem Lab Metab Chinmed Res Ctr State Adm TCM Dept Pharmaceut Ana Heping Rd 24 Harbin Heilongjiang Peoples R China;
Heilongjiang Univ Chinese Med Sinoamer Chinmed Technol Collaborat Ctr Natl TCM Key Lab Serum Pharmacochem Lab Metab Chinmed Res Ctr State Adm TCM Dept Pharmaceut Ana Heping Rd 24 Harbin Heilongjiang Peoples R China;
Guangxi Bot Garden Med Plant Natl Engn Lab Dev Southwestern Endangered Med Mat Nanning Guangxi Peoples R China;
Guangxi Bot Garden Med Plant Natl Engn Lab Dev Southwestern Endangered Med Mat Nanning Guangxi Peoples R China;
机译:靶向癌症治疗色氨酸代谢的靶向调节:系统审查
机译:结直肠癌转移的靶向治疗:对当前分子靶向治疗方法的综述以及肿瘤生物标志物在治疗转移结直肠癌中的应用
机译:对先前接受氟尿嘧啶,奥沙利铂和伊立替康+/-靶向治疗的转移性结直肠癌患者的挽救疗法的系统评价
机译:小分子ONC201 / TIC10在体外和体内靶向化疗抗性结肠直肠癌干细胞
机译:rs1042522 TP53(Arg72Pro)多态性的遗传关联研究中的基因型错误分类:对乳腺癌,肺癌,结直肠癌,卵巢癌和子宫内膜癌研究的系统评价
机译:癌症生物标记物能否使靶向治疗具有成本效益?转移性结直肠癌的系统评价
机译:靶向癌症治疗色氨酸代谢的靶向调节:系统审查